Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Improving the Continuity of patient care Through Identification and implementation of Novel patient handoff processes in Europe (HANDOVER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Netherlands,Netherlands,Sweden,Spain,Poland,Italy
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2011-09-30
Duration (months): 36.0
Total project cost (EUR): 3443100.0
EU funding (EUR): 2623200.0
Participants: 9
Project status: CLOSED

Research has shown that every year 30,000 European patients suffer preventable harm during treatment. It is estimated there were potentially 1,735 avoidable deaths in 2004. The financial cost of avoidable adverse events is reckoned at €167 million, 1% of hospitals’ total budget, due to longer hospital stays and additional treatment. Many of these adverse events relate to handoff in care. Poor continuity of clinical care (with multiple provider involvement), either at a patient’s referral to a hospital by a primary care specialist or at a patient’s discharge from the hospital, is a critical aspect of a patient’s care. Incomplete handoffs to a secondary/tertiary care unit or discharge from hospital can lead to adverse events for patients that may ultimately lead to either life threatening situations during treatment/surgery or avoidable treatment and / or re-hospitalizations after the patient’s discharge. Care transitions are especially important for vulnerable groups as the elder and the very young as for high-risk patients with multiple co-morbidities. The overall objective the HANDOVER project is optimize the continuum of clinical care at the primary care hospital interface by reducing unnecessary and avoidable treatment - medical errors and loss of life, by identifying and studying best practices and creating standardized approaches to handoff communication at the primary care hospital interface and measuring the effectiveness of these practices in terms of costs and impact. Handoffs take as many forms as there are handoff scenarios. The idea of developing a single approach for all handoffs is not likely to be possible due to the diversity and complexity of healthcare. HANDOVER will therefore aim at providing standardised basic elements in handoff processes, which can be tailored to meet local and/or institutional needs for flexibility.

Keywords: optimizing,handoffs,primary care hospital interface,best practices,standardized approaches to handoff communication,measuring effectiveness
Exploiting Gram-negative cell division targets in the test tube to obtain anti-microbial compounds (DIVINOCELL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,France,United Kingdom,United Kingdom,Chile,Netherlands,Hungary,Denmark
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2013-08-31
Duration (months): 54.0
Total project cost (EUR): 8149653.8
EU funding (EUR): 5956086.0
Participants: 12
Project status: CLOSED

The DIVINOCELL project will identify novel Gram-negative targets by exploiting the components of the divisome, their activities and interactions. It will also design selective assays for screening and will obtain a new class of antimicrobials: compounds to block bacterial division. New medicines to attack Gram-negative pathogens will decrease the burden of infectious disease and have a highly beneficial social and economic impact in Europe and beyond. Cell division is an essential and still underexploited process with excellent properties to yield new inhibitors to attack infection by blocking the proliferation of pathogens. Inhibitors directed against bacterial division targets, that are not present in eukaryotic cells, will be both effective and innocuous to humans and animals. In addition, as many of their structures will be based on interaction domains and synthetic scaffolds, they will generate resistance at levels lower than the present antibiotics. DIVINOCELL will apply existing and new knowledge on the molecular biology of Gram-negative cell division as well as novel analytical (nanodiscs), bioinformatic (molecular dynamics), structural (membrane protein crystals) and imaging (lanthanide staining) tools to exploit in the test tube the structures and interactions of targets in the divisome and the septum. DIVINOCELL will develop potent systematic screening assays and will use them to select compounds specifically tailored to inhibit the division of Gram-negatives (not precluding broad spectrum ones). Secondary activity and cell assays, based on the properties of bacterial division, will be generated to validate hits and advance them to leads. The medicinal properties of selected leads will be improved. The translational steps of the project will be developed by 4 SMEs in close collaboration with the 8 academic partners having well-proven expertise in molecular microbiology, protein chemistry, structural biology, biophysics, imaging and bioinformatics.

Keywords: anti-infectives,septation,gram-negatives,synthetic scaffolds,evolutionary genetic chemistry,protein interactions,nucleotide-binding sites,peptidoglycan,molecular dynamics,e. coli
INTEGRATION OF THE SYSTEM MODELS OF INSULIN SIGNALLING AND OF MITOCHONDRIAL FUNCTION AND ITS APPLICATION IN THE STUDY OF COMPLEX DISEASES (MITIN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Finland,United Kingdom,United Kingdom,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2011-10-31
Duration (months): 36.0
Total project cost (EUR): 3846079.0
EU funding (EUR): 2956490.0
Participants: 6
Project status: CLOSED

A common trait to disorders such as type 2 diabetes or obesity is the development of insulin resistance. There is evidence indicating the existence of a bidirectional cross-talk between insulin signalling and mitochondrial function that may be relevant for the pathogenesis of those disorders. Based on this, MITIN main goal is to identify novel mitochondrial-dependent mechanisms responsible for the development of insulin resistance. This will be done by the use of technologies of Systems Biology and the generation of computer-based tools that will permit the study of complex biological systems that integrate different regulatory networks. For the global visualization and interpretation of the “insulin signalling/mitochondria” complex system we plan to develop a computational framework that will store and integrate all possible data for each of the subsystems, both currently available data and data generated within the project by transcriptomics and lipidomics analysis. This will allow the prediction of functional associations and interactions between both processes, which will be tested under specific hypothesis-driven studies in mammalian cells, mice and Drosophila. By using a Systems Biology approach and investigating how different perturbations modulate cell transcriptomes, and lipidomes, we aim to identify integrated homeostatic responses involving the insulin signalling network and the mitochondria networks. Validation of some of the strongest associations detected by virtue of the integrated systems biology of insulin signalling/mitochondria will generate high value targets of use in therapy against Complex Diseases such as diabetes, obesity, or pathophysiological traits of the Metabolic Syndrome. Besides, computer-based tools generated in the project will be applicable to the analysis of the mechanisms that trigger other Complex Diseases.

Keywords: diabetes,insulin resistance,mitochondrial function,insulin signalling,complex diseases,systems biology,bioinformatics,profiling technologies
Molecular mechanisms of neuronal restoration: novel approaches for Parkinson's Disease (MOLPARK)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,Germany,Finland,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-04-01
End date: 2012-09-30
Duration (months): 42.0
Total project cost (EUR): 4590740.4
EU funding (EUR): 3472653.0
Participants: 7
Project status: CLOSED

MOLPARK aims to define the basic cellular and molecular mechanisms underlying the generation, differentiation, survival and connectivity of nigrostriatal dopaminergic neurons and translate this knowledge into radically new therapeutic strategies for Parkinson's disease (PD). MOLPARK brings together two industrial partners and 6 world-renowned academic groups with a uniquely advantageous knowledge platform based on complementary state-of-the-art technologies and recent relevant discoveries in their laboratories. These include, unique approaches for stem cell renewal control based on novel insights into the function of GABA receptors and intracellular signaling components such as Bex1, novel neurotrophic factors for dopaminergic neurons such as CDNF and MANF, novel approaches to harness the power of GDNF and Wnt proteins for stimulating the growth of dopaminergic terminals and novel ways to enhance synaptogenesis, MOLPARK’s strategy is based on four major interrelated objectives. I). Define the mechanisms of stem cell self-renewal, differentiation and integration and exploit these mechanisms to induce or boost existing self-repair processes with the aim of replenishing neurons in PD. 2). Define the mechanisms for sustaining dopaminergic neuron survival in health and disease with the aim of developing new, effective growth factor-based therapies aimed at protecting neurons in PD. 3). Define the mechanisms that promote the growth of DA nigrostriatal axons and dendrites with the aim of identifying therapeutic strategies based on restoring neural processes in PD. 4). Define the mechanisms that promote and sustain the synaptic connections of dopaminergic neurons with the aim of restoring connections in PD.

Keywords: parkinson's disease,neurotrophic factor,stem cells,transgenic mice,drosophila,neuronal survival,connectivity
Characterization and quantitative modeling of DNA mismatch repair and its role in the maintenance of genomic stability and cancer avoidance (MISMATCH2MODEL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,France,Netherlands,Germany,Denmark,Switzerland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2012-10-31
Duration (months): 48.0
Total project cost (EUR): 3930000.0
EU funding (EUR): 3000000.0
Participants: 6
Project status: CLOSED

Mismatch2model: Characterization and quantitative modeling of DNA mismatch repair and its role in the maintenance of genomic stability and cancer avoidance DNA mismatch repair (MMR) plays a crucial role in the maintenance of genomic stability. In both bacteria and eukaryotes, the loss of mismatch repair gives rise to a mutator phenotype. In hereditary non-polyposis colon cancer (HNPCC) families, germline mutations in one MSH2, MSH6 or MLH1 allele predispose to cancer of the colon, endometrium, ovary and other organs. HNPCC is the most frequent form of familiar cancer. In the mismatch2model project we adopt and exploit a systems biology approach in which we combine Europe’s expertise in DNA mismatch repair with sophisticated multidisciplinary technology and expertise in quantitative modeling in order to describe this DNA repair process at different levels of complexity. The multidisciplinary consortium will have the following tasks that relate directly to the topics raised in Call HEALTH 2.1.2.5: - Gather quantitative and structural data sets describing the principal steps of DNA mismatch repair - Integrate and analyze structural and functional data obtained from single molecule and bulk studies - Develop mathematical models for single and/or multiple steps of the MMR pathway - Perform analyses at different levels of complexity: from recognition of the mismatch through repairosome assembly to in vivo function - Combine the well-understood MMR E.coli model system with the cancer-protective human system The combination of the individual strengths of the multidisciplinary groups involved in this program ensures that significant progress will be made towards the understanding of this complex process.

Keywords: dna mismatch repair,systems biology,mathematical modelling,multidisciplinary,cancer
Optimizing drug safety monitoring to enhance patient safety and achieve better health outcomes (MONITORING MEDICINES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Sweden,Switzerland,Netherlands,Denmark,Ghana,United Kingdom,Morocco,Philippines,Kenya
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-09-01
End date: 2013-07-31
Duration (months): 47.0
Total project cost (EUR): 2236129.8
EU funding (EUR): 1995096.0
Participants: 11
Project status: CLOSED

Medicines are one of the most common health interventions. Expenditure on pharmaceuticals range from 10–20 % of all health expenditure in rich countries & from 20–60 % in poor countries. Knowledge of appropriate & safe medicines has grown. But the incidence of medicines adverse effects remains high. In a UK study 6.5% of hospitals admissions were related to an adverse drug reaction (ADR). And as many as 10% of hospital admissions may result in death or disease due to errors, half of which may be avoidable. There are gaps in what we know. But even where there is sufficient knowledge, brokering of that knowledge is insufficient. There is a clear & present need to build a network of stakeholders in patient safety, to strengthen information & share the evidence towards actionable learning. The EC Work Programme for 2007–2008 relating to health calls for projects that "advance the applications of evidence based medicine in Europe". This proposal will respond to that call by strengthening what we know about medicines, sharing that knowledge, & putting that knowledge to use, to reduce patient deaths & adverse effects due to medicines. Specifically, building patient safety networking to: 1. support & strengthen consumer reporting of ADRs & adverse events 2. expand the role of national pharmacovigilance centres to prevent medicine-related adverse events 3. promote better & broader use of existing pharmacovigilance data for patient safety 4. develop additional methods of pharmacovigilance to complement data from spontaneous reporting systems. Achieving these objectives will help build the scientific basis needed for making informed policy decisions on disease prevention & therapy, & management of resources for health. In particular achieving these objectives will help to identify best clinical practice, to understand decision-making in clinical settings in primary & specialized care & to foster application of evidence-based medicine & patient empowerment.

Keywords: patient safety - adverse drug events - drug use - pharmacogilance
A system view on the differential activities of human type I interferons (IFNACTION)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,France,Israel,Switzerland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-12-31
Duration (months): 48.0
Total project cost (EUR): 3761194.0
EU funding (EUR): 2866405.0
Participants: 5
Project status: CLOSED

Type I interferons (IFNs) form a restricted network of highly related immune cytokines that elicit differential biological responses through a single cell surface receptor comprised of the subunits IFNAR1 and IFNAR2. We have shown that differential signal activation correlates with differential interaction and conformational dynamics of the receptor induced by binding of different member of the IFN family. The goal of this project is to employ a systems biology approach to identify the molecular and cellular mechanisms responsible for translating receptor dynamics into differential cellular responses by combining biochemical, biophysical and genetic analysis of the signaling outputs. We will collect quantitative data describing type I interferon signaling from ligand recognition until phenomenological cellular responses in a number of well defined cell lines. Based on detailed structure functions studies, we will generate a set of IFN mutants with highly differential cellular responses. Based on this sub-family of ligands, we will explore the molecular and cellular dynamics of the signaling complex on the plasma membrane, as well as the receptor trafficking upon activation. Moreover, we will analyze the protein-protein interaction network involved in signal transduction and obtain a spatio-temporal picture of key signaling pathways. These studies will be flanked by extensive analyses of gene transcription levels and correlated with cellular responses. Using these data sets, input and output signals will be correlated on different levels by various mathematical approaches to understand how the processing of differential input signals is translated within the cell to produce different responses to binding the same surface receptors. In order to test the validity of these models, experimental and theoretical studies will be tightly coupled, for example, in designing network perturbations. As a proof-of-concept for this approach, we will design IFNs with optimized potencies for medical application, such as the ex vivo differentiation of monocytes into dendritic cell for application as cancer vaccines.

Keywords: type i interferon receptor,protein interactions,protein engineering,signal transduction,endocytosis,proteomics,ensemble modeling,structural network analysis,dendritic cells,cancer vaccines
iNTER Support Action (International Network of Teleconsultation Excellence & Referral) (ISA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Spain,Spain,Spain,Mexico,Kenya,Peru
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-09-01
End date: 2012-02-29
Duration (months): 30.0
Total project cost (EUR): 855805.0
EU funding (EUR): 779895.0
Participants: 10
Project status: CLOSED

The iNTER Support Action (iSA) Project aims to create a pilot cooperative medical support network constituted by the Hospital Son Espases (former Son Dureta) (Spain), the Instituto Valenciano de Oncología (Spain), the Hospital Vall d’Hebron (Spain), the Hospital Sant Joan de Déu (Spain), the Hospital Regional de Bata (Equatorial Guinea), the Desarrollo 2000 en África NGO (Equatorial Guinea), the Hospital Regional de Trujillo (Peru), the Instituto Nacional de Cancerología (Mexico), the St. John of God Hospital (Sierra Leone), CMF International, and the College of Health Sciences of the University of Nairobi in cooperation with the Kenyatta National Hospital (Kenya). The 30-month initiative, coordinated by Son Dureta, seeks to provide Web-based diagnostic and/or therapeutic support for complex medical cases requiring specialized opinions in different health areas (initially adults and pediatrics Oncology as well as Infectious Diseases). The communication among doctors and the sharing of medical cases will be performed by using a cost-efficient Web 2.0 portal that will facilitate the exchange of medical images, videos and reports. Strategic objectives of the project include the facilitation of communication and medical knowledge exchange to develop diagnostic, therapeutic and technological support actions within distinct healthcare settings, the encouragement of human resource, technology, and infrastructure investment policies, the implementation of multinational online Continuing Medical Education (CME) programs, the creation of clinical research groups, and the evaluation of an inexpensive Web platform for clinical case sharing.

Keywords: international support,cooperation,research network,teleconsultation,oncology,infectious diseases
Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates (TINN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: France,United Kingdom,France,United Kingdom,Netherlands,Germany,Belgium,Belgium,France,Italy,Sweden,Italy,Belgium
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2015-10-31
Duration (months): 84.0
Total project cost (EUR): 6758740.36
EU funding (EUR): 5161000.0
Participants: 16
Project status: CLOSED

The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to validate the use of these two drugs in these high risk populations, TINN involves European leaders in neonatology, paediatric pharmacology, methodology and SME and has established a close collaboration between academia, ethical bodies, regulatory authorities and pharmaceutical companies. For both drugs, the project will perform in silico experimentations, animal studies and evaluate formulations adapted to neonates. Designs will be optimized using age-appropriate state-of-the-art methods adapted to neonates, include pharmacokinetics and pharmacogenetics in order to validate the components of a Paediatric Investigation Plan. The two trials will be performed with neonatologists trained in paediatric pharmacology and clinical research who respect Good Clinical Practices. All the ethical issues related to the two trials will be considered in particular pain and distress, blood sampling (number and volume) and informed consent. Parent information sheets and consent form submitted to parents’ associations for approval. TINN will include short-term safety (based on vital signs, blood safety data and function of the major organs) and potential for long-term adverse reactions. Results will be also reported in order to allow a PUMA application and to improve neonatal care, through scientific societies. Therefore, TINN will strengthen the European role in drug evaluation in paediatric patients and will support initiatives of the European pharmaceutical industry. Increasing the appropriate use of medicines in child will be of direct benefit to children, their families and health professionals.

Keywords: ciprofloxacine,fluconazole,infection,emea list,puma,pip,clinical trial,preterm and term neonates,pharmacokinetics,pharmacogenetics